Richard D Dortch1, Lindsey M Dethrage2, John C Gore2, Seth A Smith2, Jun Li2. 1. From the Department of Radiology and Radiological Sciences (R.D.D., J.C.G., S.A.S.), Vanderbilt University Institute of Imaging Science (R.D.D., L.M.D., J.C.G., S.A.S.), and the Departments of Biomedical Engineering (R.D.D., J.C.G., S.A.S.), Physics and Astronomy (J.C.G., S.A.S.), Molecular Physiology and Biophysics (J.C.G.), and Neurology (J.L.), Vanderbilt University, Nashville, TN. richard.dortch@vanderbilt.edu. 2. From the Department of Radiology and Radiological Sciences (R.D.D., J.C.G., S.A.S.), Vanderbilt University Institute of Imaging Science (R.D.D., L.M.D., J.C.G., S.A.S.), and the Departments of Biomedical Engineering (R.D.D., J.C.G., S.A.S.), Physics and Astronomy (J.C.G., S.A.S.), Molecular Physiology and Biophysics (J.C.G.), and Neurology (J.L.), Vanderbilt University, Nashville, TN.
Abstract
OBJECTIVE: The objectives of this study were (1) to develop a novel magnetization transfer ratio (MTR) MRI assay of the proximal sciatic nerve (SN), which is inaccessible via current tools for assessing peripheral nerves, and (2) to evaluate the resulting MTR values as a potential biomarker of myelin content changes in patients with Charcot-Marie-Tooth (CMT) diseases. METHODS: MTR was measured in the SN of patients with CMT type 1A (CMT1A, n = 10), CMT type 2A (CMT2A, n = 3), hereditary neuropathy with liability to pressure palsies (n = 3), and healthy controls (n = 21). Additional patients without a genetically confirmed subtype (n = 4), but whose family histories and electrophysiologic tests were consistent with CMT, were also included. The relationship between MTR and clinical neuropathy scores was assessed, and the interscan and inter-rater reliability of MTR was estimated. RESULTS: Mean volumetric MTR values were significantly decreased in the SN of patients with CMT1A (33.8 ± 3.3 percent units) and CMT2A (31.5 ± 1.9 percent units) relative to controls (37.2 ± 2.3 percent units). A significant relationship between MTR and disability scores was also detected (p = 0.01 for genetically confirmed patients only, p = 0.04 for all patients). From interscan and inter-rater reliability analyses, proximal nerve MTR values were repeatable at the slicewise and mean volumetric levels. CONCLUSIONS: MTR measurements may be a viable biomarker of proximal nerve pathology in patients with CMT.
OBJECTIVE: The objectives of this study were (1) to develop a novel magnetization transfer ratio (MTR) MRI assay of the proximal sciatic nerve (SN), which is inaccessible via current tools for assessing peripheral nerves, and (2) to evaluate the resulting MTR values as a potential biomarker of myelin content changes in patients with Charcot-Marie-Tooth (CMT) diseases. METHODS: MTR was measured in the SN of patients with CMT type 1A (CMT1A, n = 10), CMT type 2A (CMT2A, n = 3), hereditary neuropathy with liability to pressure palsies (n = 3), and healthy controls (n = 21). Additional patients without a genetically confirmed subtype (n = 4), but whose family histories and electrophysiologic tests were consistent with CMT, were also included. The relationship between MTR and clinical neuropathy scores was assessed, and the interscan and inter-rater reliability of MTR was estimated. RESULTS: Mean volumetric MTR values were significantly decreased in the SN of patients with CMT1A (33.8 ± 3.3 percent units) and CMT2A (31.5 ± 1.9 percent units) relative to controls (37.2 ± 2.3 percent units). A significant relationship between MTR and disability scores was also detected (p = 0.01 for genetically confirmed patients only, p = 0.04 for all patients). From interscan and inter-rater reliability analyses, proximal nerve MTR values were repeatable at the slicewise and mean volumetric levels. CONCLUSIONS: MTR measurements may be a viable biomarker of proximal nerve pathology in patients with CMT.
Authors: Luca Padua; D Pareyson; I Aprile; T Cavallaro; D A Quattrone; N Rizzuto; G Vita; P Tonali; A Schenone Journal: Neurol Sci Date: 2009-12-17 Impact factor: 3.307
Authors: K W Chung; B C Suh; M E Shy; S Y Cho; J H Yoo; S W Park; H Moon; K D Park; K G Choi; S Kim; S B Kim; D S Shim; S M Kim; I N Sunwoo; B O Choi Journal: Neuromuscul Disord Date: 2008-07-07 Impact factor: 4.296
Authors: Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson Journal: J Peripher Nerv Syst Date: 2011-09 Impact factor: 3.494
Authors: Davide Pareyson; Mary M Reilly; Angelo Schenone; Gian Maria Fabrizi; Tiziana Cavallaro; Lucio Santoro; Giuseppe Vita; Aldo Quattrone; Luca Padua; Franco Gemignani; Francesco Visioli; Matilde Laurà; Davide Radice; Daniela Calabrese; Richard A C Hughes; Alessandra Solari Journal: Lancet Neurol Date: 2011-04 Impact factor: 44.182
Authors: Richard D Dortch; Francesca Bagnato; Daniel F Gochberg; John C Gore; Seth A Smith Journal: Magn Reson Med Date: 2018-03-24 Impact factor: 4.668
Authors: Alex K Smith; Richard D Dortch; Lindsey M Dethrage; Bailey D Lyttle; Hakmook Kang; E Brian Welch; Seth A Smith Journal: Magn Reson Med Date: 2016-04-01 Impact factor: 4.668
Authors: Sean Ekins; Nadia K Litterman; Renée J G Arnold; Robert W Burgess; Joel S Freundlich; Steven J Gray; Joseph J Higgins; Brett Langley; Dianna E Willis; Lucia Notterpek; David Pleasure; Michael W Sereda; Allison Moore Journal: F1000Res Date: 2015-02-26